Eravacycline is a novel broad-spectrum fluorocycline antibiotic being developed for a wide range of serious infections. Eravacycline was efficacious in mouse septicemia models, demonstrating 50% protective dose (PD 50 ) 
T
he rising number of infections caused by multidrug-resistant bacteria is a serious public health threat (1) . A recent study concluded that the spread of resistant pathogens has resulted in higher health care and societal costs and longer hospital stays (2) . Current therapies often fail to completely eradicate the bacterial infection, leading to higher levels of resistance development as well as increased morbidity and mortality. Further, the lack of appropriate antibiotic treatment could compromise successful outcomes in the growing number of elderly patients and patients undergoing surgery, transplantation, and chemotherapy (3) . The Infectious Diseases Society of America (IDSA) has singled out a set of "ESKAPE" pathogens, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, which currently cause the majority of U.S. hospital infections and effectively "escape" the effects of antibacterial drugs (3, 4) . In a campaign to stoke the current pipeline with new antibacterial agents targeting ESKAPE pathogens, the IDSA recently proposed the 10 ϫ =20 initiative to encourage global political, scientific, industry, economic, intellectual property, policy, medical, and philanthropic leaders to develop creative incentives to stimulate antibacterial research and development, with a goal to develop 10 effective antibiotics by 2020 (5) .
Eravacycline is a new broad-spectrum fluorocycline antibiotic with in vitro potency against emerging multidrug-resistant Gramnegative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae and Acinetobacter baumannii (6) . Eravacycline maintains activity in clinical isolates expressing major antibiotic resistance mechanisms, including tetracycline-specific efflux and ribosomal protection mechanisms (6, 7) . When the less prevalent tetracycline-specific mechanism tet(X) is recombinantly overexpressed in Escherichia coli, the MIC of eravacycline increases, similar to that of other tetracyclines (7) . In a phase 2 trial in complicated intraabdominal infections (cIAI), an intravenous (i.v.) formulation of eravacycline was (i) clinically effective against a broad spectrum of pathogens, including ESBL-positive and carbapenem-resistant Gram-negative isolates (test of cure, 92.9% for eravacycline at 1.5 mg/kg of body weight every 24 h or 100% for eravacycline at 1.0 mg/kg every 12 h in the microbiologically evaluable population), (ii) safe and well-tolerated, and (iii) capable of being administered in a convenient dosing regimen (8) . Phase 1 studies have shown that eravacycline is orally bioavailable, is safe and well tolerated, and has potential to be used as an oral step-down therapy (9) . Eravacycline is currently in phase 3 clinical studies for the i.v./oral treatment of complicated urinary tract infections (cUTI) and the i.v. treatment of cIAI.
Eravacycline was evaluated in multiple preclinical efficacy models of serious hospital-and community-acquired infections. Eravacycline has ϳ30% oral bioavailability in humans (9); however, because of low oral bioavailability in preclinical species used for toxicology and efficacy models (10) , preclinical evaluations of eravacycline required intravenous administration. The objective of these animal infection studies was to demonstrate the efficacy of eravacycline in mouse models of infection to support its ongoing clinical development. Antibiotics and media. Eravacycline was synthesized at Tetraphase Pharmaceuticals as described in Xiao et al. (11) . Tigecycline for injection (Pfizer, Groton, CT) was purchased from Skenderian Apothecary, Cambridge, MA. Linezolid, vancomycin, imipenem, meropenem, cilastatin, tetracycline, and levofloxacin were from Henry Schein Veterinary Supply (Melville, NY) or Sigma-Aldrich (St. Louis, MO). Trypticase soy agar (TSA), TSA II agar plates, and brain heart infusion broth (BHI) were from BBL (Franklin Lakes, NJ). Cyclophosphamide and type III hog gastric mucin were obtained from Sigma-Aldrich.
MATERIALS AND METHODS
In vitro susceptibility testing. MIC microdilution assays were performed according to Clinical and Laboratory Standards Institute methodology (12, 13) .
Mice. All studies were performed at ViviSource, an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility, under approved institutional animal care and use committee (IACUC) protocols, and conformed to the Office of Laboratory Animal Welfare (OLAW) standards. Pathogen-free female mice, CD-1 or BALB/c, purchased from Charles River Laboratories, Inc. (Wilmington, MA), were acclimated for a minimum of 5 days prior to the start of the studies. The animals had free access to food and water throughout the study.
Preparation of inocula. (i) Systemic infection model. S. aureus
ATCC 13709 log-phase bacteria grown at 37°C in BHI were diluted in 5% hog gastric mucin. For S. aureus SA161 and SA192, S. pyogenes ATCC 8668 and ATCC 19615, and E. coli ATCC 25922 and EC133 inocula, bacteria grown overnight on TSA at 37°C under 5% CO 2 were resuspended in saline to an optical density of 0.1 at 625 nm. Bacterial suspensions were then diluted in BHI and further diluted in 8% hog gastric mucin to achieve the infecting inocula.
(ii) Thigh infection, lung infection, and pyelonephritis models. Bacteria were grown at 37°C on TSA in 5% CO 2 overnight. The optimized bacterial concentration was prepared by suspending a portion of the overnight growth in sterile saline to achieve an optical density of 0.1 at 625 nm. The culture was subsequently diluted in BHI (thigh and lung models) or saline (pyelonephritis model) to achieve the infecting inocula.
Data analysis. All data were analyzed using GraphPad Prism (version 4.03; GraphPad Software). For systemic infection studies, at the termination of the study (48 h postinfection), percent survival was calculated, and the dose (mg/kg) affecting 50% survival, the 50% protective dose (PD 50 ), was reported along with 95% confidence intervals (95% CI) as calculated by probit analysis. For thigh infection models, the amount of compound required to achieve 1, 2, and 3 log 10 reductions relative to the value for untreated mice 24 h posttreatment was calculated using a linear line plot of the mean log 10 CFU per gram of thigh versus compound dose. For lung and pyelonephritis models, log 10 CFU per gram of lung or kidney was graphed, and statistically significant differences between groups were calculated by nonparametric Mann-Whitney analysis.
Mouse systemic infection model. Inocula were optimized to achieve a bacterial inoculum that resulted in 100% mortality in CD-1 mice (18 to 20 g, n ϭ 6 per group) infected by the intraperitoneal (i.p.) route (0.5 ml) within 48 h postinfection. Mice received a single treatment with drug formulated in sterile 0.9% saline ranging from 0.05 to 10 mg/kg in a dose volume of 10 ml/kg via tail vein intravenous injection 1 h after i.p. infection. Inocula were serially diluted, plated on TSA, and incubated overnight to determine the bacterial concentration. Inocula used in these experiments were as follows (in CFU per mouse): S. aureus ATCC 13709, 5 CFU/ml of bacteria in a 0.1-ml volume by intramuscular injection into the right thigh. At 1.5 h postinfection, mice received a single dose of drug formulated in sterile 0.9% saline ranging from 0.3 to 30 mg/kg in a dose volume of 10 ml/kg via a tail vein i.v. injection. At the time of bacterial burden determination (pretreatment and 24 h posttreatment), mice were euthanized by CO 2 inhalation, their right thighs were aseptically removed, weighed, and homogenized in sterile saline, and the homogenate was serially diluted and plated on TSA. CFU per gram of thigh were calculated after overnight incubation of TSA plates at 37°C in 5% CO 2 . Inocula used in these experiments were as follows (in CFU per mouse): S. aureus ATCC 13709, 2.99 ϫ 10 5 ; S. aureus SA161, 2.6 ϫ 10 5 ; S. aureus SA192, 2.83 ϫ 10 5 ; S. aureus SA158, 1.5 ϫ 10 5 ; and S. pyogenes ATCC 8668, 1.9 ϫ 10 5 . Mouse lung infection model. BALB/c mice (18 to 20 g, n ϭ 4 to 6 per group) were inoculated with 50 l of the prepared bacterial inoculum via intranasal inhalation under light anesthesia (4.5% isoflurane with 1.5 liters/min O 2 ). Mice received drug formulated in sterile 0.9% saline in 10 ml/kg via tail vein i.v. injection or via oral gavage in water (linezolid only) at 2 and 12 h postinfection. At the time of bacterial burden determination (pretreatment and 24 h after initiation of treatment), mice were euthanized by CO 2 inhalation, the lungs of the mice were aseptically removed, weighed, and homogenized in sterile saline, and the homogenate was serially diluted and plated on TSA. CFU per gram of lung were calculated after overnight incubation of TSA plates at 37°C in 5% CO 2 . Inocula used in these experiments were as follows (in CFU per mouse): S. aureus SA191, 7.5 ϫ 10 7 ; and S. pneumoniae SP160, 7.0 ϫ 10 6 . Mouse pyelonephritis model with E. coli EC200. BALB/c mice (18 to 20 g, n ϭ 4 to 6 per group) were inoculated with 0.2 ml of prepared bacterial inoculum via intravenous injection to seed the kidney. Animals were administered antibiotics formulated in sterile 0.9% saline at 10 ml/kg i.v. via the tail vein 12 and 24 h postinfection. At the time of bacterial burden determination (initiation of treatment and 12 h after treatment termination), mice were euthanized by CO 2 inhalation, the kidneys of the mice were aseptically removed, weighed, and homogenized in sterile saline, and the homogenate was serially diluted and plated on TSA. CFU per gram of kidney were calculated after overnight incubation at 37°C in 5% CO 2 . The log 10 CFU per gram of kidney was graphed using GraphPad Prism (version 4.03). The inoculum was 1.3 ϫ 10 8 CFU per mouse.
RESULTS

Antibacterial activity of eravacycline and comparators against isolates used in infection models.
Eravacycline showed potent antibacterial activity (Table 1) ranging from Յ0.016 to 0.5 g/ml.
The presence of tetracycline-specific resistance genes such as tet(M) (strains SA161, SA191, and SP160), tet(K) (strains SA158 and SA192), and tet(B) (strains EC133 and EC200) has been shown in previous work to have minimal or no effect on the antibacterial potency of eravacycline (6, 7) . Eravacycline protection in a mouse septicemia model with susceptible and tetracycline-resistant isolates. In mouse systemic infection models, eravacycline exhibited potent efficacy when administered as a single i.v. dose, producing PD 50 values ranging from 0.05 to 4.4 mg/kg (Table 2) . Eravacycline PD 50 values of 0.30, 1.0, and 0.30 mg/kg were similar to those of tigecycline against S. aureus ATCC 13709 and MRSA strains SA161 and SA192, respectively, regardless of tetracycline resistance. Tetracycline was found to be relatively inactive (PD 50 of Ͼ10 mg/kg) against SA161 and SA192, and vancomycin had a PD 50 value of 0.30 mg/kg against SA192. Eravacycline was more potent than tigecycline against both S. pyogenes isolates, ATCC 8668 and ATCC 19615, with eravacycline PD 50 values of 1.0 and ϳ0.05 mg/kg versus tigecycline PD 50 values of 2.5 and 0.30 mg/kg, respectively. Linezolid was relatively inactive against S. pyogenes ATCC 8668 (PD 50 of Ͼ10 mg/kg) but had a PD 50 value of 0.63 mg/kg against S. pyogenes ATCC 19615. For E. coli ATCC 25922, the PD 50 value of eravacycline (4.4 mg/kg) was 2.5-fold higher than that of tigecycline (1.7 mg/kg); however, the 95% confidence values were broad for eravacycline. For E. coli EC133, the PD 50 value of eravacycline was ϳ3-fold lower than that of tigecycline (1.2 versus 3.5 mg/kg, respectively), and the PD 50 value for imipenem was Ͻ0.3 mg/kg.
Efficacy of eravacycline in a mouse thigh infection model with susceptible and tetracycline-resistant isolates. Single doses of eravacycline and comparator antibiotics were evaluated in mouse thigh infection models with S. aureus and S. pyogenes infections (Table 3 ). All treatment-related CFU reductions in each thigh model were compared to the values for the corresponding 24-hour untreated controls. Against S. aureus ATCC 13709, eravacycline produced 1, 2, and 3 log 10 CFU reductions at 5-to 7.5-fold lower doses (0.2, 0.2, and 0.4 mg/kg, respectively) than tigecycline (1.2, 1.5, and 2 mg/kg, respectively). For MRSA SA161, eravacycline showed 5-to 12.5-fold greater potency than tigecycline, producing 1, 2, and 3 log 10 CFU reductions at 0.6, 1, and 3 mg/kg, respectively, versus 3, 12.5, and 17.3 mg/kg, respectively, for tigecycline. For SA161, vancomycin showed 1, 2, and 3 log 10 CFU reductions at 0.8, 2.9, and 10 mg/kg. Against MRSA SA192, S. aureus SA158, and S. pyogenes ATCC 8668, eravacycline produced similar log 10 CFU reductions at doses within Ͻ2-fold of those of tigecycline (Table 3) . For SA158, vancomycin showed 1 and 2 log 10 CFU reductions at 2.8 and Ͼ20 mg/kg, and linezolid was relatively inactive against S. pyogenes ATCC 8668, requiring Ͼ20 mg/kg to produce a 1 log 10 CFU reduction.
Efficacy of eravacycline in mouse lung infection models with tetracycline-resistant S. pneumoniae and MRSA isolates. In a lung infection model with S. pneumoniae tet(M) isolate SP160, two doses of eravacycline given i.v., at 2 and 12 h postinfection, produced log 10 CFU reductions in the lung bacterial burden of 2.6, 3.1, and 3.9 at 3, 6, and 12 mg/kg, respectively, versus the values for 24-hour untreated controls (Fig. 1A) . All eravacycline dosages exceeded the efficacy of linezolid given orally at 30 mg/kg, producing a 2.0 log 10 CFU reduction. For lung infections with MRSA SA191, when dosed at 2 and 12 h postinfection, eravacycline given at 10 mg/kg i.v. produced a 2.4 log 10 CFU reduction versus the values for the 24-hour untreated controls. This reduction was similar to that for linezolid given at 30 mg/kg orally and exceeded the efficacy of vancomycin given at 50 mg/kg i.v., which produced a 1.4 log 10 CFU reduction versus the value for the 24-hour untreated controls (Fig. 1B) .
Efficacy of eravacycline in mouse pyelonephritis models with uropathogenic tetracycline-resistant E. coli. At 2, 5, and 10 mg/kg administered i.v. at 12 and 24 h postinfection, eravacycline produced (Fig. 2) . In the same model, levofloxacin at 2 mg/kg given i.v. produced a 4.9 log 10 CFU reduction.
DISCUSSION
Eravacycline was efficacious in mouse models of serious hospital-and community-acquired infections. Eravacycline provided significant protection against Gram-positive pathogens in neutropenic thigh infection models, against septicemia following peritoneal challenge, and in pneumonia models when challenge bacteria were hospitaland community-acquired MRSA, S. pneumoniae, or S. pyogenes. Against the Gram-negative pathogen E. coli, the highest-incidence pathogen in cIAI and cUTI, eravacycline showed potent efficacy in septicemia and pyelonephritis models. In agreement with the preclinical efficacy demonstrated in the present studies, eravacycline was shown to be efficacious in a phase 2 study for complicated intraabdominal infections (8) . Together, these data support the advancement of eravacycline into pivotal phase 3 trials under way for the treatment of cIAI and cUTI. Eravacycline was active in mouse infection models against isolates expressing both tetracycline-specific efflux [tet(K) and tet(B)] and ribosomal protection [tet(M)] mechanisms. In earlier work, the in vitro antibacterial activity of eravacycline was shown to be minimally affected by expression of tetracycline-specific mechanisms in clinical isolates or resistance to other major antibiotic classes, including fluoroquinolones, macrolides, aminoglycosides, ␤-lactams, cephalosporins, and carbapenems (6, 7) . The management of cIAI and cUTI and other complicated infections has become increasingly difficult due to emerging resistance in Gram-negative bacteria to all of these cornerstone antibiotic classes (14, 15, 16) . Its demonstrated preclinical and clinical efficacies continue to support eravacycline as a promising new i.v. and oral antibiotic option for the treatment of cIAI, cUTI, and other serious infections with a high incidence of drug-resistant Gram-negative and Gram-positive pathogens.
